First Trust Advisors LP Has $76.65 Million Stock Position in Charles River Laboratories Intl. Inc (NYSE:CRL)

First Trust Advisors LP lowered its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 37.5% during the third quarter, Holdings Channel.com reports. The fund owned 579,077 shares of the medical research company’s stock after selling 347,847 shares during the period. First Trust Advisors LP’s holdings in Charles River Laboratories Intl. were worth $76,652,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Squar Milner Financial Services LLC increased its position in Charles River Laboratories Intl. by 253.2% during the third quarter. Squar Milner Financial Services LLC now owns 219 shares of the medical research company’s stock worth $28,000 after buying an additional 157 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new position in Charles River Laboratories Intl. during the third quarter worth approximately $33,000. Flagship Harbor Advisors LLC increased its position in Charles River Laboratories Intl. by 132.1% during the second quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock worth $45,000 after buying an additional 181 shares during the last quarter. CWM LLC increased its position in Charles River Laboratories Intl. by 75.9% during the third quarter. CWM LLC now owns 387 shares of the medical research company’s stock worth $51,000 after buying an additional 167 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC acquired a new position in Charles River Laboratories Intl. during the second quarter worth approximately $69,000. 94.31% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the sale, the insider now owns 19,327 shares in the company, valued at $2,519,467.72. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.80% of the company’s stock.

A number of equities analysts have weighed in on the company. ValuEngine downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Bank of America downgraded Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price target on the stock. in a research report on Friday, October 18th. Credit Suisse Group set a $138.00 price target on Charles River Laboratories Intl. and gave the stock a “hold” rating in a research report on Friday, September 13th. UBS Group lowered their price target on Charles River Laboratories Intl. from $147.00 to $145.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, SunTrust Banks boosted their price target on Charles River Laboratories Intl. from $156.00 to $162.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $150.50.

Shares of NYSE:CRL opened at $130.51 on Friday. Charles River Laboratories Intl. Inc has a 12-month low of $103.00 and a 12-month high of $149.07. The stock has a market cap of $6.23 billion, a PE ratio of 21.64, a P/E/G ratio of 2.00 and a beta of 1.08. The business has a 50 day moving average of $132.15 and a 200-day moving average of $133.41. The company has a quick ratio of 1.38, a current ratio of 1.59 and a debt-to-equity ratio of 1.47.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.05. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The company had revenue of $668.00 million during the quarter, compared to analysts’ expectations of $674.08 million. During the same quarter in the previous year, the company posted $1.53 earnings per share. The business’s revenue was up 14.1% on a year-over-year basis. Equities research analysts expect that Charles River Laboratories Intl. Inc will post 6.53 earnings per share for the current year.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: The primary rules of Elliott Wave theory

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.